NCT06343311 - T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

B-Cell Non-Hodgkin's Lymphoma (NHL)Lymphoma, Non-HodgkinsLymphomas Non-Hodgkin's B-CellNon-Hodgkin LymphomaNon-Hodgkin's LymphomaLarge B-Cell LymphomaLymphoma, Non-Hodgkin's, AdultLymphomaRefractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaLymphoma, Non-HodgkinHIV Associated LymphomaCNS LymphomaHigh-grade B-cell LymphomaRefractory B-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

EB103

EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene.

Trial Locations (2)

75246

RECRUITING

Baylor Scott & White Research Institute, Texas Oncology, Dallas

95817

RECRUITING

University of California, Davis, Sacramento